Clinical Trial Stage
Funds clinical trials advancing stem cell and genetic therapies for unmet medical needs, emphasizing regulatory approval, patient access, and strategic support from CIRM.
Funder: California Institute for Regenerative Medicine
Due Dates: July 31, 2026 (2 PM PT) | January, April, October 2026 (anticipated, last business day, 2 PM PT)
Funding Amounts: Up to $8M (for-profit, phase 1) | $12M (non-profit, phase 1) | $15M (any org, phase 2/3); max 4 years
Summary: Supports clinical trials of stem cell-based and genetic therapies for diseases with unmet needs, emphasizing comprehensive clinical development and patient access.
Key Information: Open to California and non-California orgs; co-funding required for for-profits and some non-profits; at least one CA trial site is mandatory.
Description
This opportunity funds the clinical development of stem cell-based and genetic therapies targeting diseases with significant unmet medical needs. The program supports interventional phase 1, 2, or 3 clinical trials, including pivotal trials, with an emphasis on comprehensive strategies for regulatory approval, equitable access, and pre-commercialization planning. CIRM acts as both a funder and strategic partner, offering subject matter expertise and infrastructure resources to accelerate the path to market and maximize patient benefit.
